Elixir Medical Corporation

Since 2005, the company has continually sought to improve the treatment of vascular disease with:

- Drug-eluting coronary stent systems (DES)
- Fully resorbable drug-eluting scaffold systems (BRS)
- Drug-eluting coronary bioadaptor systems

Its latest innovation — the DynamX™ Coronary Bioadaptor System — is designed to be a significant advancement beyond drug-eluting stents (DES).

Elixir Medical’s innovations are designed to make a meaningful change in patients’ lives. The company does not simply want to engineer a better medical device. Saving lives and helping patients enjoy their daily life is what drives us every day.